Benjamin Edwards Inc. Reduces Stock Position in Zoetis Inc. $ZTS

Benjamin Edwards Inc. lessened its stake in Zoetis Inc. (NYSE:ZTS) by 61.7% in the second quarter, HoldingsChannel reports. The firm owned 88,566 shares of the company’s stock after selling 142,600 shares during the period. Benjamin Edwards Inc.’s holdings in Zoetis were worth $6,364,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Prosperity Bancshares Inc purchased a new position in Zoetis in the fourth quarter worth about $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Zoetis during the 1st quarter valued at about $28,000. Elyxium Wealth LLC bought a new position in shares of Zoetis in the 4th quarter worth approximately $32,000. Root Financial Partners LLC lifted its stake in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares during the period. Finally, Wellington Grp LLC boosted its holdings in shares of Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after buying an additional 267 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ZTS has been the subject of several recent research reports. Cantor Fitzgerald set a $94.00 target price on shares of Zoetis in a research report on Tuesday, August 25th. JPMorgan Chase & Co. dropped their price target on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. TD Cowen cut their price objective on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. Argus restated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Finally, UBS Group decreased their target price on Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $107.43.

Zoetis Stock Up 0.1%

Shares of ZTS stock opened at $77.45 on Monday. The company has a market capitalization of $32.00 billion, a price-to-earnings ratio of 12.76, a PEG ratio of 1.80 and a beta of 0.73. Zoetis Inc. has a one year low of $71.00 and a one year high of $156.49. The company’s fifty day moving average price is $75.57 and its 200-day moving average price is $95.40. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. Zoetis’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.